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1. Apart from prospective, randomized clinical trials, clinicians need to take observational, pop-
ulation based registry studies into account for optimized chronic myeloid leukemia (CML) 
management. (this thesis)
2. The quality of response monitoring and patient outcome in CML might benefit from cen-
tralization of care in hospitals and expert centers, treating at least two new CML patients 
each year. (this thesis)
3. Monitoring response to tyrosine kinase inhibitor (TKI) therapy in chronic phase CML 
patients can reliably be performed by molecular monitoring, thereby allowing to omit rou-
tine cytogenetic response monitoring. (this thesis)
4. The EUTOS long term survival (ELTS)-risk score should be used for identification of patients 
who benefit most from upfront treatment with a second generation TKI. (this thesis) 
5. Addition of pegylated interferon-alpha (IFN) to nilotinib therapy in patients, who fail to 
achieve a deep molecular response to imatinib, should not be recommended because of 
IFN-related toxicities and efficacy of nilotinib alone. (this thesis)
6. Identification of CML patients in deep molecular remission who meet strict criteria required 
for TKI discontinuation and referral of these patients to physicians with known experience 
with TKI discontinuation should become a routine part of clinical practice in CML (Hughes 
et al., Blood, 2016;128(1):17-23)
7. Improved identification of advanced phase CML may be performed by adhering to the 
European Leukemia Net (ELN) definition instead of the World Health Organization (WHO) 
definition, which less clearly discriminates overall survival from CML patients with chronic 
phase CML. (Geelen et al., Eur J Haematol 2017;99:381-382)
8. Therapy adherence is a critical success factor for CML treatment as ‘Drugs don’t work in 
patients who don’t take them’ (C. Everett Koop, 1985)
9. Scientific journals should abandon Kaplan-Meier methodology in the analysis of end points 
with competing risks. (Schumacher et al., J Clin Epidemiol, 2016;80:135-136)
10. ‘Tis much better to do a little with certainty & leave the rest for others that come after than to 
explain all things by conjecture without making sure of any thing.’ (Isaac Newton, unpublished 
notes for the Preface of Opticks, 1704)
11. A true ‘homo universalis’ does not only visit the conference, but also joins the ‘fun run’.
